AzTrials
AzTrials

Infection; Cesarean SectionNCT02865993

Betadine Irrigation in Cesarean Section

A study testing betadine group and no betadine group in people with Infection; Cesarean Section, run by Campus Bio-Medico University at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to evaluate, for the first time in Literature, the effects of betadine washing versus normal saline washing after uterine closure in women undergoing cesarean section (CS) at ≥36 gestational weeks in terms of post CS infections, complication, fever and pain. Read more about this study

Who is it for?
Ages 18 to 50 years, women onlyHealthy volunteers can take part
Conditions the study is for
Infection; Cesarean Section
What is being tested?
betadine group and no betadine group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteItaly
Study dates
Sep 2015to Jun 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • women aged 18-50 years
  • planned or urgent cesarean section (CS)
  • gestational age > 36 weeks
  • written informed consent

Who cannot join

  • suspected or known allergy to iodine

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • campus bio-medico of Rome

    Rome, 00128

Other trials in Italy

About this study

Official title: May Betadine Improve Cesarean Section Outcomes?

The purpose of this study was to evaluate, for the first time in Literature, the effects of betadine washing versus normal saline washing after uterine closure in women undergoing cesarean section (CS) at ≥36 gestational weeks in terms of post CS infections, complication, fever and pain.

Read the detailed description

This was a single-centre randomized controlled trial performed at Department of Obstetrics and Gynecology of San Camillo Hospital of Rome. The protocol was approved by the Internal Review Board. All women having a cesarean section (CS) were eligible for recruitment unless there was suspected or known allergy to iodine. The study was widely publicized around obstetrics unit and all women were provided antenatally with a brief statement regarding the study. The study was presented to women as part of hospital initiative to reduce postoperative infections and to improve postoperative recovery. Consent was obtained from all women at the time of consenting for CS.

Background was recorded for each patient: maternal age, gestational week at delivery, BMI, and pregnancy complication; plural fetal pregnancies, premature rupture of membranes, placenta previa and pre-eclampsia. The investigators recorded the type of cesarean procedure, elective (scheduled operations) or urgent (patients in labor and maternal or fetal emergent indication), mean surgical time to perform CS.

In Literature, povidone-iodine irrigation has been demonstrated to be a simple and inexpensive solution with the potential to prevent surgical site infection , which can also reduce the incidence of intra-abdominal infectious complications when used as an intraperitoneal irrigant in patients undergoing bacterially-contaminated surgical procedures, i.e. orthopedic, general surgery, oncologic surgery. Therefore, the investigators aimed to test its use in CS.

Patients were intra-operatively randomized to receive intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline or with only normal saline solution. Randomization to 'Betadine' or 'no Betadine' group was performed using sequentially numbered sealed opaque envelopes that contained the allocation. The allocation was prepared using computer generated list of random numbers using a variable block of 10 and performed by a staff members, part of the clinical team. After all layers were sutured and just prior to starting skin closure, the envelope with the allocation was opened by one of the theatre nurse.

All CS were generally performed under spinal anesthesia by the specialist obstetricians, credentialed trainee registrars or by juniors in the presence of a specialist obstetrician using the modified Misgav Ladach surgical technique.

An abdominal opening was made through a straight transverse incision, which was placed 3-4 cm above the symphysis. The subcutaneous tissue was left untouched apart from the midline. The rectus sheath was separated along its fibers and the rectus muscles separated by pulling. Stretching with index fingers opened the peritoneum and the uterus was opened with an index finger. The hole was enlarged between the index finger of one hand and the thumb of the other.

Single-layer closure of the uterine incision was performed as follows: a holding Vicryl-0 was placed in the left corner to stabilize and define the demarcation of the suture line. A continuous non-locking stitch beginning at the right corner was used, closing the whole thickness of the uterine wall, excluding the decidual layer, in a cranial/caudal position. Additional single sutures were added for hemostasis if required. Routinely exteriorization of the uterus was not performed. The visceral and parietal peritoneal layers were left open and the rectus muscle was not stitched. The rectus sheath was stitched with a continuous non-locking Vicryl-0 and the subdermal space was closed in all patients. All patients had preoperative exams not longer than 4 weeks prior the CS and received prophylactic intravenous antibiotics (amoxicillin 2 g and metronidazole 1 g) preoperatively to reduce the rate of wound infection. In addition, all patients received oxytocin intravenous during CS and 20 IU was administered by an intravenous drip running post surgical procedure. All patients were encouraged to start breastfeeding during early postoperative care, supported by a midwife and by a nurse specialized in newborn care after admission to the maternity ward.

Post CS infections included:

  • Postpartum endometritis: defined as a clinical diagnosis, usually involving fever, uterine fundal tenderness, or purulent lochia requiring antibiotic therapy.
  • Postoperative wound infection: defined as erythema, tenderness, purulent drainage from the incision site, with or without fever, requiring antibiotic therapy.
  • Postoperative fever: defined as greater than 38 degrees C or 100.4 degrees F.
  • Postoperative wound seroma or hematoma: defined as collection of serous fluid or blood/clot in the subcutaneous area of the incision.
  • Composite wound complications: defined as the presence of any one of the following: wound infection, seroma, hematoma, separation.

Patients were examined during daily rounds whilst in hospital about intestinal recanalization, postoperative mobilization, postoperative 24h post CS pain and wounds. Preoperative and postoperative exams, presence of fever or any symptoms have been accurately registered.

After discharge from the hospital, the women were sent a letter with addressed return envelope to report any post CS problems at four weeks after surgery as part of hospital surveillance policy. Charts of all women readmitted for any reason were reviewed. Differences between 'Betadine' and 'no Betadine' groups were assessed using chi square for categorical data test. Fisher's exact test was used where there were 5 or fewer counts within a category and t-test for continuous data. Relative risk (RR) and the corresponding 95% confidence interval (CI) were calculated. A P value of <0.05 was considered statistically significant.

Being tested
betadine group, no betadine group
Keywords
cesarean section, cesarean section complications, betadine irrigation
Medical subject headings
Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • betadine groupOther

    Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.

  • no betadine groupOther

    Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.

Study groups in NCT02865993
Study groupRoleWhat they receive
Betadine GroupOtherPatients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
Receives: Other: betadine group
No Betadine GroupOtherPatients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
Receives: Other: no betadine group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of postoperative infections

    postoperative infections expressed in number of patients with postoperative infections, such as endometritis or wood infections up to 20 days after cesarean section

    Measured: up to 20 days after cesarean section

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2016 (estimated)
  2. Study startSep 2015
  3. Primary completionMar 2016
  4. Study completionJun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02865993
Sponsor's protocol ID
BetadineCS0405
Status last verified
Jul 2016
First submitted
27 Jul 2016
Last updated
15 Aug 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing betadine group and no betadine group in people with Infection; Cesarean Section, run by Campus Bio-Medico University at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of postoperative infections (time frame: up to 20 days after cesarean section). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in